Abstract:Sarcopenia is a skeletal muscle disease that often manifests with aging, characterized in part by low skeletal muscle strength and mass as well as low physical performance (i.e., exercise intolerance) compared to young adults, which contributes to increased frailty. There remains a need to develop novel and adherable interventions for mitigating these losses with aging. Increased flavonoid consumption is inversely related to frailty in mid-life/older adults. Late-life oral supplementation with the natural flavonoid apigenin can improve select age-related conditions; however, its effect on treating features of sarcopenia is unkown. Hypothesis. We hypothesized that late-life oral supplementation with apigenin would result in greater grip strength and skeletal muscle mass, increased exercise tolerance, and lower frailty with aging. Methods. Young (Y; 6 mo) and old (O; 27 mo) male C57BL/6N mice consumed drinking water containing vehicle (control [C]; 0.2% carboxymethylcellulose; YC, n=10; OC, n=7) or apigenin (Api; 0.5 mg/mL in vehicle; Y-Api, n=10; O-Api, n=9]) for 6 weeks. Skeletal muscle strength was measured by forelimb grip strength. Skeletal muscle mass was assessed as quadriceps weight relative to body mass. Exercise tolerance was determined using a rota-rod and quantified as time spent running while the rota-rod accelerated from 50-100% of maximal running speed. Frailty was evaluated using a validated frailty index. Exercise tolerance was assessed before and after the intervention, and skeletal muscle strength, mass, and frailty were quantified at the end of the intervention. Data are reported as mean±SEM. Results. Forelimb grip strength. Forelimb grip strength (g of force/bodyweight) was higher in YC vs. OC (6.7±0.3 vs 5.3±0.2, P=0.001) and in O-Api (6.1±0.2, P=0.006 vs OC). However, O-Api was still lower than Y-Api (YApi, 6.9±0.3, P=0.025 vs O-Api). There were no differences between Y-Api and YC ( P=0.520). Quadriceps mass. Quadriceps mass (mg/bodyweight) was higher in YC vs OC (9.5±0.6 vs 7.8±0.4, P=0.051), in O-Api vs OC (O-Api, 9.9±0.6; P=0.005 vs OC), and in Y-Api vs YC (11.1±0.5, P =0.064 vs YC). O-Api was not different than Y-Api ( P=0.111). Exercise tolerance. Prior to the intervention we observed differences with aging (YC, 1233±141 sec vs OC, 614±128 sec; P=0.010), but no differences between treatment groups (YC vs Y-Api, P=0.115; OC vs O-Api, P=0.177). Following the intervention, exercise tolerance was increased in the O-Api group (pre: 443±50 sec vs post: 1118±113 sec, P<0.001) but unchanged in other groups ( P=0.137-0.543). Frailty. Frailty index was higher in OC vs YC (0.24±0.02 vs 0.02±0.01, P<0.001). Frailty in O-Api mice was higher than Y-Api (0.18±0.01 vs 0.02±0.01 P<0.001), but lower than OC ( P=0.005). There were no differences between Conclusions. Oral supplementation with apigenin may be an effective therapeutic strategy to treat select characteristics of sarcopenia and associated frailty with aging. NIH AG055822-02S1, K99 HL159241, H2020-MSCA-IF-2019: 892267, T32 DK007135 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Oligonol Alleviates Sarcopenia by Regulation of Signaling Pathways Involved in Protein Turnover and Mitochondrial Quality

Oligonol®, an Oligomerized Polyphenol from Litchi chinensis, Enhances Branched-Chain Amino Acid Transportation and Catabolism to Alleviate Sarcopenia

Oligonol, a Low-Molecular Weight Polyphenol Derived from Lychee, Alleviates Muscle Loss in Diabetes by Suppressing Atrogin-1 and MuRF1

Oligonol promotes anti-aging pathways via modulation of SIRT1-AMPK-Autophagy Pathway

Beneficial Effects of Walnut Oligopeptides on Muscle Loss in Senescence-Accelerated Mouse Prone-8 (SAMP8) Mice: Focusing on Mitochondrial Function

Allulose Attenuated Age-Associated Sarcopenia via Regulating IGF-1 and Myostatin in Aged Mice

Beneficial Effects of a Mixture of Algae and Extra Virgin Olive Oils on the Age-Induced Alterations of Rodent Skeletal Muscle: Role of HDAC-4

Olive Leaf Extract Supplementation to Old Wistar Rats Attenuates Aging-Induced Sarcopenia and Increases Insulin Sensitivity in Adipose Tissue and Skeletal Muscle

Nobiletin Improves D-Galactose-Induced Aging Mice Skeletal Muscle Atrophy by Regulating Protein Homeostasis

Orcinol Glucoside Improves Senile Osteoporosis through Attenuating Oxidative Stress and Autophagy of Osteoclast via Activating Nrf2/Keap1 and mTOR Signaling Pathway

Maintaining myoprotein and redox homeostasis via an orally recharged nanoparticulate supplement potentiates sarcopenia treatment

Oleanolic acid alleviates obesity‐induced skeletal muscle atrophy via the PI3K/Akt signaling pathway

Potential nutritional strategies to prevent and reverse sarcopenia in aging process: Role of fish oil-derived ω-3 polyunsaturated fatty acids, wheat oligopeptide and their combined intervention

Wheat seedlings extract ameliorates sarcopenia in aged mice by regulating protein synthesis and degradation with anti-inflammatory and mitochondrial biogenesis effects

Campanumoea Javanica Bl. Activates the PI3K/AKT/mTOR Signaling Pathway and Reduces Sarcopenia in a T2DM Rat Model

EFFECTS OF FLAVANOL (+)-EPICATECHIN ON SKELETAL MUSCLE OF AGED RATS

Proteome network analysis of skeletal muscle in lignan-enriched nutmeg extract-fed aged mice

Neuroprotective treatment with the nitrone compound OKN-007 mitigates age-related muscle weakness in aging mice

Aerobic Exercise Improves Mitochondrial Function in Sarcopenia Mice Through Sestrin2 in an AMPKα2-Dependent Manner.

Late-life oral supplementation with apigenin mitigates loss of skeletal muscle strength and mass, exercise intolerance, and frailty with aging in mice

Synergistic Effects of MFG-E8 and Whey Protein on Mitigating D-Galactose-induced Sarcopenia Through PI3K/AKT/PGC-1α and MAPK/ERK Signaling Pathways